U.S.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

Mark One

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2025

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to _______

Commission File No. 333-255178

TRANSUITE.ORG INC.

(Exact name of registrant as specified in its charter)

Nevada

7370

30-1129581

(State or Other Jurisdiction of

Incorporation or Organization)

(Primary Standard Industrial

Classification Number)

(IRS Employer

Identification Number)

732 S 6th St# 4304

Las Vegas NV 89101

775-295-4295

(Address and telephone number of principal executive offices)

Indicate by checkmark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
(Do not check if a smaller reporting company)		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Applicable Only to Issuer Involved in Bankruptcy Proceedings During the Preceding Five Years. N/A

Indicate by checkmark whether the issuer has filed all documents and reports required to be filed by Section 12, 13 and 15(d) of the Securities Exchange Act of 1934 after the distribution of securities under a plan confirmed by a court. Yes ☐ No ☒

Indicate the number of shares outstanding of each of the registrant’s classes of common stock as of the latest practicable date.

1460,~~415~~059,093 Shares of Common Stock as of ~~August~~November 1117, 2025

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION
Item 1.	Unaudited Condensed Consolidated Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	19
Item 4.	Controls and Procedures	2019
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	2120
Item 1A.	Risk Factors	2120
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2120
Item 3.	Defaults Upon Senior Securities	2120
Item 4.	Mine Safety Disclosures	2120
Item 5.	Other Information	2120
Item 6.	Exhibits	2220
SIGNATURES		2321

Table of Contents

Transuite.Org Inc.

Condensed Consolidated Balance Sheets

	June 30,			December 31,
	September 30,			December 31,
	2025			2024
	(Unaudited)			(Audited)
ASSETS
Current Assets
Bank	$	100		$	-
Cash and cash equivalents	$	14,030		$	-
Fund held in trust		-			16,103
Accounts receivable		5015,000			-
Due from related party		15,000			15,000
Other receivable and prepayment		16,062			-
Prepaid		10,680			-
Due from related party		-			15,000
Deferred Share Issuance Cost		254,750			-
Deferred share issuance cost		254,750			-
Total Current Assets	$	~~330~~299,~~530~~842		$	31,103
Other Assets
Intangible assets, net		34,075			40,531
Goodwill		12,501,149			-
Total Assets	$	364,605		$	71,634
Intangible assets, net		24,607,847			40,531
Total Assets	$	37,408,838		$	71,634
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued liabilities	$	5285,~~899~~353		$	66,367
Accrued interest		1014,~~373~~477			3,253
Due to related party		253,~~170~~212			2,154
Convertible note		-			153,520
Total Current Liabilities		88,442			225,294
Stock payable		50,000			-
Loan payable		202,062			148,442
Total Current Liabilities		153,042			225,294
Total Liabilities		290,504			373,736
Loan payable		172,062			148,442
Commitments and Contingencies (Note 10)
Contingent liability		22,875,281			-
Total Liabilities		23,200,385			373,736
Commitments and Contingencies (Note 12)
STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock: $0.001 par value, 75,000,000 shares authorized, 12,915,093 shares and 4,046,760 shares issued and outstanding, respectively		12,915			4,047
Common Stock: $0.001 par value, 75,000,000 shares authorized, 47,869,093 shares and 4,046,760 shares issued and outstanding, respectively		47,869			4,047
Additional paid-in capital		742,~~598~~592,~~345~~082			143,843
Accumulated deficit		(728,~~545~~429,~~784~~710	)		(458,919	)
Total equity (deficit) attributed to Transuite.Org. Inc.		6514,~~476~~210,241			(311,029	)
Non-controlling interest		8(1,~~625~~788	)		8,927
Total Stockholders' Equity (Deficit)		7414,~~101~~208,453			(302,102	)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$	~~364~~37,~~605~~408,838		$	71,634

The accompanying notes are an integral part of the condensed consolidated financial statements.

3 Table of Contents

Transuite.Org Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

	Three Months Ended						~~Six~~Nine Months Ended
	June 30,						June 30,
	September 30,						September 30,
	2025			2024			2025			2024
Revenues	$	5065,000		$	-		$	50115,000		$	-
Operating Expenses
General and administrative expenses	$	~~820~~6,321		$	-		$	~~923~~8,520		$	-
Professional fees (including stock-based compensation of $6,651,250 and $0 for three months ended June 30, 2025 and 2024 and $7,060,100 and $0 for six months ended June 30, 2025 and 2024, respectively)		6,641,396			39,386			7,121,393			85,046
Professional fees (including stock-based compensation of $20,878,790 and $0 for three months ended September 30, 2025 and 2024 and $27,938,890 and $0 for nine months ended September 30, 2025 and 2024, respectively)		20,929,582			186,797			28,050,975			271,843
Amortization		3,228			3,~~228~~386			69,~~456~~684			69,~~456~~842
Total operating expenses		620,~~645~~939,~~444~~131			42190,~~614~~183			728,~~128~~069,~~772~~179			91281,~~502~~685
Net loss from operations		(620,~~595~~874,~~444~~131	)		(42190,~~614~~183	)		(727,~~078~~954,~~772~~179	)		(91281,~~502~~685	)
Other expense
Interest expense		(4,~~050~~105	)		~~(2,658~~-	)		(711,~~119~~224	)		(3,987	)
Other expense		(1,276	)		-			(1,276	)		-
Total other expense		(4,105	)		-			(11,224	)		(3,987	)
Total other expense		(5,326	)		(2,658	)		(8,395	)		(3,987	)
Net loss before taxes		(20,878,236	)		(190,183	)		(27,965,403	)		(285,672	)
Net loss before taxes		(6,600,770	)		(45,272	)		(7,087,167	)		(95,489	)
Provision for income taxes		-			-			-			-
Net loss	$	(620,~~600~~878,~~770~~236	)	$	(45190,~~272~~183	)	$	(727,~~087~~965,~~167~~403	)	$	(95285,~~489~~672	)
Less: Net loss attributable to non-controlling interest		(~~152~~685	)		-			(~~302~~685	)		-
Net loss attributable to Transuite.Org. Inc.	$	(6,600,618	)	$	(45,272	)	$	(7,086,865	)	$	(95,489	)
Net loss attributable to Transuite.Org.Inc.	$	(20,877,551	)	$	(190,183	)	$	(27,964,718	)	$	(285,672	)
Net Loss Per Common Share – Basic and Diluted	$	(0.5896	)	$	(0.0105	)	$	(02.8315	)	$	(0.0207	)
Weighted Average Common Shares Outstanding		1121,~~429~~803,~~324~~604			4,046,760			813,~~538~~009,~~938~~081			4,046,760

The accompanying notes are an integral part of the condensed consolidated financial statements.

4 Table of Contents

Transuite.Org Inc.

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

For the six months ended ~~June~~September 30, 2025 and ~~June~~September 30, 2024

(Unaudited)

For ~~six~~nine months ended ~~June~~September 30, 2025

					Additional									Non-			TotalShareholders'
	Common stock				AdditionalPaid-in			Accumulated						Non-controlling			TotalShareholders'Equity
	Common stock				Paid-in			Accumulated						controlling			Equity
	Shares		Amount		Capital			Deficit			Total			Interest			(Deficit)
Balance, December 31, 2024 (Audited)		4,046,760	$	4,047	$	143,843		$	(458,919	)	$	(311,029	)	$	8,927		$	(302,102	)
Stock-based compensation		221,000		221		408,629			-			408,850			-			408,850
Issuance of common stock as commitment shares		135,000		135		249,615			-			249,750			-			249,750
Issuance of common stock for conversion of convertible note		5,117,333		5,117		148,403			-			153,520			-			153,520
Net loss		-		-		-			(486,247	)		(486,247	)		(150	)		(486,397	)
Balance, March 31, 2025 (Unaudited)		9,520,093	$	9,520	$	950,490		$	(945,166	)	$	14,844		$	8,777		$	23,~~622~~621
Stock-based compensation		3,395,000		3,395		6,647,855			-			6,651,250			-			6,651,250
Net loss		-		-		-			(6,600,618	)		(6,600,618	)		(152	)		(6,600,770	)
Balance, June 30, 2025 (Unaudited)		12,915,093	$	12,915	$	7,598,345		$	(7,545,784	)	$	65,476		$	8,625		$	74,101
Stock-based compensation		11,954,000		11,954		20,816,836			-			20,828,790			-			20,828,790
Issuance of common stock for acquisition of Goldfinch Group Holdings Ltd.		3,000,000		3,000		(3,000	)		(6,375	)		(6,375	)		(8,625	)		(15,000	)
Issuance of common stock for acquisition of SolanAI Global Ltd.		10,000,000		10,000		12,489,901			-			12,499,901			(1,103	)		12,498,798
Issuance of common stock for acquisition of Xirangsheng (Shenzhen) Health Technology Co., Ltd.		10,000,000		10,000		1,690,000			-			1,700,000			-			1,700,000
Net loss		-		-		-			(20,877,551	)		(20,877,551	)		(685	)		(20,878,236	)
Balance, September 30, 2025 (Unaudited)		47,869,093	$	47,869	$	42,592,082		$	(28,429,710	)	$	14,210,241		$	(1,788	)	$	14,208,453

For ~~six~~nine months ended ~~June~~September 30, 2024

					Additional								Non-		Total
	Common stock				AdditionalPaid-in		Accumulated						Non-controlling		TotalShareholders'
	Common stock				Paid-in		Accumulated						controlling		Shareholders'
	Shares		Amount		Capital		Deficit			Total			Interest		Deficit
Balance, December 31, 2023 (Unaudited)		4,046,760	$	4,047	$	35,826	$	(89,398	)	$	(49,525	)	$	-	$	(49,525	)
Imputed interest		-		-		1,329		-			1,329			-		1,329
Net loss		-		-		-		(50,217	)		(50,217	)		-		(50,217	)
Balance, March 31, 2024 (Unaudited)		4,046,760	$	4,047	$	37,155	$	(139,615	)	$	(98,413	)	$	-	$	(98,413	)
Imputed interest		-		-		1,992		-			1,992			-		1,992
Net loss		-		-		-		(45,272	)		(45,272	)		-		(45,272	)
Balance, June 30, 2024 (Unaudited)		4,046,760	$	4,047	$	39,147	$	(184,887	)	$	(141,693	)	$	-	$	(141,693	)
Forgiveness of loan payable to related party		-		-		104,696		-			104,696			-		104,696
Net loss		-		-		-		(190,183	)		(190,183	)		-		(190,183	)
Balance, September 30, 2024 (Unaudited)		4,046,760	$	4,047	$	143,843	$	(375,070	)	$	(227,180	)	$	-	$	(227,180	)

The accompanying notes are an integral part of the condensed consolidated financial statements.

5 Table of Contents

Transuite.Org Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Six Months Ended
	Nine Months Ended
	June 30,
	September 30,
	2025			2024
Cash Flows from Operating Activities:
Net loss	$	(727,~~087~~965,~~167~~403	)	$	(95285,~~489~~672	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization		69,~~456~~684			69,~~456~~842
Imputed interest		-			3,321
Share-based compensation		727,~~060~~938,~~100~~890			-
Changes in operating assets and liabilities:
Accounts receivable		(5015,000	)		-
Prepaid		(10,680	)		54,060
Prepaid Expense		(6,675	)		98,640
Deferred Share Issuance Cost		(5,000	)		-
Accounts payable and accrued liabilities		~~(13~~4,~~468~~071	)		(349,~~374~~992	)
Accrued Interest		711,~~120~~224			-
Net Cash Used in Operating Activities		(9228,~~639~~209	)		(35123,~~026~~877	)
Cash Flows from Investing Activities:
Net funds from acquisition of Xirangsheng (Shenzhen) Health Technology Co., Ltd.		1,458			-
Net Cash Provided by Investing Activities		1,458			-
Cash Flows from Financing Activities:
Proceeds from loans		53,620			-
Proceeds from loan payable – related parties		23,016			35,026
Repayment of loans		(30,000	)		-
Net Cash Provided by Financing Activities		76,636			35,026
Proceed from related party		2,013			-
Net Change in Cash and Cash Equivalents		(16,003	)		-
Proceeds from loan payable – related parties		23,045			163,625
Repayment of loan payable – related party		(24,000	)		-
Net Cash Provided by Financing Activities		24,678			163,625
Net Change in Cash and Cash Equivalents		(2,073	)		39,748
Cash and Cash Equivalents, beginning of period		16,103			10,815
Cash and Cash Equivalents, end of period	$	~~100~~14,030		$	1050,~~815~~563
Cash consists of:
Cash at bank	$	14,030		$	10,815
Funds held in trust		-			-
	$	14,030		$	10,815
Supplemental Disclosure Information:
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-
Non-Cash Disclosure:
Forgiveness of loan payable to related party	$	-		$	104,696
Issuance of common stock as commitment shares	$	249,750		$	-
Conversion of convertible notes payable	$	153,520		$	-
Issuance of common stock for acquisition of Goldfinch Group Holdings Ltd.	$	15,000		$	-
Issuance of common stock for acquisition of SolanAI Global Ltd.	$	12,500,000		$	-
Issuance of common stock for acquisition of Xirangsheng (Shenzhen) Health Technology Co., Ltd.	$	1,700,000		$	-

The accompanying notes are an integral part of the condensed consolidated financial statements.

63 Table of Contents

Transuite.Org Inc.

Notes to the Condensed Consolidated Financial Statements

~~June~~September 30, 2025

(Unaudited)

NOTE 1 - NATURE OF OPERATIONS

Transuite.Org Inc. ("TRSO") is a Nevada-incorporated artificial intelligence solutions provider founded on June 15, 2018, with its common shares publicly traded on the OTCQB market under the symbol TRSO. As an SEC-reporting issuer, the company maintains a steadfast commitment to delivering sustainable value to shareholders through innovative AI technologies.

Led by top AI scientists and powered by elite research team, TRSO has developed the world-leading AI Social Agent platform. This groundbreaking technology integrates multimodal intelligence, real-time translation, deviation correction learning, knowledge fusion, and complex reasoning capabilities - creating the most creative AI "super employees" that deliver extraordinary value to enterprises. As the global pioneer in "AI Workforce as a Service" (AWaaS), our innovative model enables enterprises to either rent or purchase AI employees as permanent knowledge assets, setting the global standard for enterprise AI adoption.

TRSO has established itself as a leader in AI-driven business solutions, offering pioneering AI Social Agent platforms for global enterprises. We are dedicated to making AI workforce deployment more accessible and efficient, enabling businesses to meet growing demands for intelligent automation. Our platform allows enterprises to rapidly deploy industry-specific AI social agents that integrate natively with major global platforms including WhatsApp, Telegram, and WeChat. These advanced agents deliver 24/7, hyper-realistic customer interactions while automating complex business processes, ultimately driving superior operational outcomes. Our mission centers on empowering organizations to build their AI workforce, enhance efficiency, and transform customer engagement through our revolutionary technology.

Building upon our AI social agent foundation, TRSO is developing a comprehensive AI ecosystem that combines multimodal intelligence, seamless social platform integration, and sophisticated business process automation. This strategic expansion positions the company at the vanguard of AI innovation, addressing evolving enterprise needs across multiple sectors including healthcare, e-commerce, and education.

The company benefits from the leadership of an internationally recognized team with roots in Tsinghua University, bringing more than ten years of specialized expertise in artificial intelligence, machine learning, natural language processing, and enterprise-grade solutions. Through our proprietary technologies and deep experience in large-scale AI model implementation, TRSO develops transformative solutions that help businesses successfully navigate the AI revolution while delivering concrete, measurable value to users worldwide.

On November 24, 2024, the Company and other founders formed Goldfinch Group Holdings Ltd. In which the Company holds a 70% controlling interest.

~~NOTE~~On August 8, 2025, the Company entered into a share exchange agreement with Fidelity World Holdings Ltd. for the acquisition of the remaining 30% equity interest in Goldfinch Group Holdings Ltd. through the issuance of 3,000,000 restricted common shares at $2.00 –per ~~SUMMARY~~share OFwith ~~SIGNIFICANT~~a ~~ACCOUNTING~~fair ~~POLICIES~~of $6,000,000. Upon the completion of the transaction, the Goldfinch Group Holdings Ltd. become wholly owned subsidiary of the Company.

On August 25, 2025, the Company entered into a share exchange agreement with Crestar Holdings Ltd., wholly owned subsidiary of Goldfinch Group Holdings Ltd., and Hailiang Li for the acquisition of 51% equity interest in SolanAI Global Ltd., a Hong Kong AI technology company, through the issuance of 10,000,000 restricted common shares at $1.25 per share with a fair value of $12,500,000 as initial consideration. The Company may issue up to 5,000,000 additional shares based on independent SolanAI’s valuation completed within 120 days, subject to Board approval and additional SEC disclosure. On August 25, 2025, the Company completed the acquisition of 51% of SolanAI.

Table of Contents

On September 15, 2025, the Company entered into a Letter of Intent (“LOI”) with Fujian Wochong Intelligent Technology Co., Ltd. (“Wochong”) outlining a proposed transaction for the acquisition of 51% of the equity interest in Wochong through the issuance of common stock. The LOI stipulates that the transaction will be executed based on the mutually agreed valuation of Wochong, which is to be determined upon completion of due diligence. The agreement is subject to several conditions, including satisfactory due diligence results, approval by the boards of directors of both companies, the absence of any material adverse changes, and obtaining all necessary third-party consents. The LOI includes mutual confidentiality provisions and grants either party the right to terminate the agreement in writing should the due diligence results prove unsatisfactory.

On September 26, 2025, the Company entered into a Letter of Intent (“LOI”) with SYD GOLDX PTY LTD (“SGX”) outlining a proposed transaction for the acquisition of 51% of the equity interest in SGX, an Australian licensed Digital Currency Exchange, through the issuance of common stock. The LOI provides that the parties will negotiate in good faith to enter into a definitive agreement, subject to satisfactory completion of due diligence, negotiation of final terms, approval by the boards of directors of both companies, and other customary conditions. The LOI includes mutual confidentiality provisions and grants either party the right to terminate the agreement in writing should the due diligence results prove unsatisfactory.

On September 30, 2025, the Company entered into a share exchange agreement with Crestar Holdings Ltd., wholly owned subsidiary of Goldfinch Group Holdings Ltd., and Hailiang Li for the acquisition of 100% equity interest in Xirangsheng (Shenzhen) Health Technology Co., Ltd. (“XRS”), an innovative enterprise based on the combination of AI Social Agent and Traditional Chinese Medicine, through the issuance of 10,000,000 restricted common shares at $0.17 per share with a fair value $1,700,000 as initial consideration. The Company may issue additional shares within 60 days after receipt of the independent valuation of XRS upon terms agreed on the Agreement, subject to Board approval and compliance with applicable securities laws. On September 30, 2025, the Company completed the acquisition of 100% of XRS.

NOTE 2 – GOING CONCERN

The Company’s financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.

As reflected in the financial statements, the Company had an accumulated deficit of $28,429,710 at September 30, 2025 and negative operating cash flow of $28,209 for nine months ended September 30, 2025.

The Company's ability to continue as a going concern is contingent upon achieving future profitable operations and securing necessary financing to meet operational obligations. Management plans to fund operations over the next twelve months through existing cash reserves, loans from related parties, and potential capital raises via public or private offerings. While management is confident in its ability to obtain financing, generate revenue, meet regulatory requirements, and achieve commercial objectives, there can be no assurance that such funding will be secured or that future operations will be successful.

To improve its financial position, the Company has implemented a comprehensive strategy focused on:

	1.	Revenue Growth – Expanding contracts with government and multinational clients while enhancing global service delivery capabilities
	2.	Strategic Expansion – Acquiring high-potential AI and Web3 projects to strengthen technology offerings and attract top talent
	3.	Market Development – Increasing participation in global industry events and executing targeted brand-building initiatives
	4.	Technology Advancement – Systematically filing patents to protect core innovations and build intellectual property assets

Management believes these initiatives will drive sustained financial improvement. The Company will continue to monitor and report on their operational and financial progress.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the ~~six~~nine months ended ~~June~~September 30, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for fiscal year 2024 have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended December 31, 2024 included in the Company’s Form 10-KT as filed with the Securities and Exchange Commission on March 28, 2025.

7 Table of Contents

Basis of Consolidation

These consolidated financial statements include the accounts of the Company, ~~and~~ its ~~70%~~wholly owned subsidiaries of Goldfinch Group Holdings Ltd. (including its wholly owned subsidiary Crestar Holding Ltd.) and Xirangsheng (Shenzhen) Health Technology Co., Ltd. and 51% owned SolanAI Global Ltd.. All material intercompany balances and transactions have been eliminated.

Foreign Currency Translations

The Company’s functional and reporting currency is the U.S. dollar. Xirangsheng (Shenzhen) Health Technology Co., Ltd.’s, SolanAI Global Ltd.’s and Goldfinch Group Holdings Ltd.’s functional currency is the Chinese Renminbi (RMB). All transactions initiated in RMB are translated into U.S. dollars in accordance with ASC 830-30, “Translation of Financial Statements,” as follows:

	1)	Monetary assets and liabilities at the rate of exchange in effect at the balance sheet date.
	2)	Equity at historical rates.
	3)	Revenue and expense items at the average rate of exchange prevailing during the period.

Table of Contents

Adjustments arising from such translations are deferred until realization and are included as a separate component of stockholders’ equity as a component of comprehensive income or loss. Therefore, translation adjustments are not included in determining net income (loss) but reported as other comprehensive income (loss). Gains and losses from foreign currency transactions are included in earnings in the period of settlement.

	Nine Months Ended
	September 30,
	2025		2024
Spot USD:RMB exchange rate		0.14044		-
Average USD:RMB exchange rate		0.14044		-

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value of Financial Instruments

ASC 820, “Fair Value Measurements and Disclosures”, defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:

Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.

Level 3 - inputs to the valuation methodology are unobservable and significant to the fair value.

The carrying amounts of financial instruments such as accounts payable and note payable approximate their fair values because of the short maturity of these instruments.

Business Combinations

In accordance with Accounting Standards Codification (“ASC”) 805-10, Business Combinations (“ASC 805-10”), the Company accounts for all business combinations using the acquisition method of accounting. Under this method, assets and liabilities, including any remaining non-controlling interests, are recognized at fair value at the date of acquisition. The excess of the purchase price over the fair value of assets acquired, net of liabilities assumed, and non-controlling interests is recognized as goodwill. Certain adjustments to the assessed fair values of the assets, liabilities, or non-controlling interests made subsequent to the acquisition date, but within the measurement period, which is up to one year, are recorded as adjustments to goodwill. Any adjustments subsequent to the measurement period are recorded in income. Any cost or equity method interest that the Company holds in the acquired company prior to the acquisition is re-measured to fair value at acquisition with a resulting gain or loss recognized in income for the difference between fair value and the existing book value. Results of operations of the acquired entity are included in the Company’s results from the date of the acquisition onward and include amortization expense arising from acquired tangible and intangible assets.

Table of Contents

Cash and Cash Equivalents

For the purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. As of ~~June~~September 30, 2025 and December 31, 2024, the Company had bank balance of $~~100~~14,030 and $0, respectively.

Funds held in trust comprise funds held in a trust account by the Company’s legal counsel. As of ~~June~~September 30, 2025 and December 31, 2024, the Company had $0 and $16,103 in funds held in trust, which are also considered cash equivalent.

Accounts Receivable

Accounts receivables are recorded in accordance with ASC 310, “Receivables,” at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company does not currently have any amount recorded as an allowance for doubtful accounts. Based on the management’s estimate and based on all accounts being current, the Company has not deemed it necessary to reserve for doubtful accounts at this time.

As of ~~June~~September 30, 2025 and December 31, 2024, ~~the Company had~~ accounts receivable ofwas $5015,000 and $0, respectively.

8 Table of Contents

Prepaid Expenses

Prepaid expenses are amounts paid to secure the use of assets or the receipt of services at a future date or continuously over one or more future periods. When the prepaid expenses are eventually consumed, they are charged to expense.

As of ~~June~~September 30, 2025 and December 31, 2024, there were $1016,~~680~~062 and $0 in ~~prepaid~~other ~~expenses,~~receivable ~~respectively.~~and ~~The prepaid balance as of June 30~~prepayment, ~~2025 is related to annual fee of OTCQB amortized straight-line over the 12-month term which commenced on March 01, 2025~~respectively. ~~During~~ ~~the six months ended June 30, 2025, we incurred $5,340 of filing expense.~~

Goodwill

The Company accounts for goodwill in accordance with ASC 350 “Intangibles-Goodwill and Other.”

ASC 350 requires that goodwill and other intangibles with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value. In addition, ASC 350 requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis and between annual tests when circumstances indicate that the recoverability of the carrying amount of goodwill may be in doubt. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assigning assets and liabilities to reporting units, assigning goodwill to reporting units, and determining the fair value. Significant judgments required to estimate the fair value of reporting units include estimating future cash flows, determining appropriate discount rates and other assumptions. Changes in these estimates and assumptions or the occurrence of one or more confirming events in future periods could cause the actual results or outcomes to materially differ from such estimates and could also affect the determination of fair value and/or goodwill impairment at future reporting dates.

As of September 30, 2025, goodwill of $12,501,149 was generated through the acquisition of 51% equity interest in SolanAI Global Ltd. (Note 9)

Intangible Asset

The Company accounts for its intangible assets in accordance with ASC Subtopic 350-40, Internal-Use Software-Computer Software Developed or Obtained for Internal Use, and ASC Subtopic 360-10, Accounting for the Impairment or Disposal of Long-Lived Assets. ASC Subtopic 350-40 requires assets to be recorded at the cost to develop the asset and requires an intangible asset to be amortized over its useful life and for the useful life to be evaluated every reporting period to determine whether events or circumstances warrant a revision to the remaining period of amortization. If the estimate of useful life is changed the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life.

We capitalized website development and databases costs of $64,500, which is being amortized over a 5-year life. During the ~~six~~nine months ended ~~June~~September 30, 2025 and ~~June~~September 30, 2024, we recognized $69,~~456~~684 and $69,~~456~~842 worth of amortization expense, respectively. As of ~~June~~September 30, 2025 and December 31, 2024, the ~~intangible~~website ~~assets~~development and database cost were $3433,~~075~~653 and $40,531, net of accumulated amortization of $3033,~~425~~653 and $23,969.

On September 30, 2025, the Company acquired AI Social Agent for Traditional Chinese Medicine of $24,577,000 from the acquisition of Xirangsheng (Shenzhen) Health Technology Co., Ltd.

As of September 30, 2025 and December 31, 2024, the total intangible assets were $24,607,847 and $40,531, net of accumulated amortization of $33,653 and $23,969.

Long lived Assets

Long-lived assets are evaluated for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value.

Table of Contents

Commitments and Contingencies

Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made. Contingent assets are not recognized in the financial statements. A contingent asset is disclosed where an inflow of economic benefits is probable. Contingent assets are assessed continually and, if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognized in the period in which the change occurs.

Related Party Balances and Transactions

The Company follows FASB ASC 850, “Related Party Disclosures,” for the identification of related parties and disclosure of related party transaction.

Convertible Financial Instruments

The Company account for our convertible financial instruments in accordance with ASC 470-20 “Debt with Conversion and Other Options.” The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting; and, (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU2020-06 removes from U.S. GAAP the separation models for (1) convertible debt with a cash conversion feature (“CCF”) and (2) convertible instruments with a beneficial conversion feature (“BCF”). With the adoption of ASU2020-06, entities will not separately present in equity an embedded beneficial conversion feature from the convertible debts.

9 Table of Contents

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, “Revenue Recognition” following the five steps procedure:

Step 1: Identify the contract(s) with customers

Step 2: Identify the performance obligations in the contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price to performance obligations

Step 5: Recognize revenue when the entity satisfies a performance obligation

The Company’s revenue derives from its AI-Driven Ecosystem Product Planning consulting service which enhances client’s operational capabilities, market reach, and technological infrastructure in the live e-commerce sector. InDuring ~~June 2025,~~ the ~~Company~~nine ~~completed~~months ~~two~~ended ~~core~~September ~~service~~30, ~~contents~~2025, ~~“Research~~the ~~and~~Company ~~Analysis” and “Strategic Proposal Development” and~~ recognized service revenue of $50115,000.

Share-Based Compensation

The Company accounts for share-based compensation under the fair value method in accordance with ASC 718, “Compensation – Stock Compensation,” which requires all such compensation to employees and non-employees to be calculated based on its fair value of the equity instrument at the grant date and recognized in the earnings over the requisite service or vesting period.

During the ~~six~~nine months ended ~~June~~September 30, 2025 and 2024, the Company recorded $727,~~060~~938,~~100~~890 and $0 in stock-based compensation, respectively. The stock-based compensation incurred from common stock awarded to consultants was reported under professional fees in the statements of operation.

Table of Contents

Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net income per share is computed similar to basic net income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. If applicable, diluted net income per share assumes the conversion, exercise or issuance of all common stock instruments, such as convertible notes, unless the effect is to reduce a loss or increase earnings per share.

For the ~~six~~nine months ended ~~June~~September 30, 2025 and 2024, the following convertible note was excluded from the computation of diluted net loss per shares as the result of the computation was anti-dilutive:

	June 30,		June 30,
	September 30,		September 30,
	2025		2024
	(Shares)		(Shares)
Convertible Notes		-		5,117,333

Recent Accounting Pronouncements

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures ("ASU 2023-09"), which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. The Company has not yet adopted this standard and is currently evaluating the impact this update will have on its financial statements and disclosures retrospectively upon the future adoption.

In July 2025, the FASB issued Accounting Standards Update 2025-05, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets (“ASU 2025-05”). ASU 2025-05 provides a practical expedient that all entities can use when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under ASC 606, Revenue from Contracts with Customers. Under this practical expedient, an entity is allowed to assume that the current conditions it has applied in determining credit loss allowances for current accounts receivable and current contract assets remain unchanged for the remaining life of those assets. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025, and interim reporting periods in those years. Entities that elect the practical expedient and, if applicable, make the accounting policy election are required to apply the amendments prospectively. We are currently evaluating the potential impact of adopting ASU 2025-05 on our consolidated financial statements and disclosures.

We have evaluated all other recently issued, but not yet effective, accounting pronouncements and do not believe that these accounting pronouncements will have any material impact on our consolidated financial statements or disclosures upon adoption.

10 Table of Contents

Recent Adopted Accounting Standards

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures ("ASU 2023-07"), which require public companies disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment's profit or loss and assets that are currently required annually. The guidance is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The adoption of ASU 2023-07 has not had a material effect on the Company’s statements and disclosures.

NOTE 3 – GOING CONCERN

As reflected in the financial statements, the Company had an accumulated deficit of $7,545,784 at June 30, 2025 and negative operating cash flow of $92,639 for six months ended June 30, 2025.

To improve its financial position, the Company has implemented a comprehensive strategy focused on:

1. Revenue Growth – Expanding contracts with government and multinational clients while enhancing global service delivery capabilities 2. Strategic Expansion – Acquiring high-potential AI and Web3 projects to strengthen technology offerings and attract top talent 3. Market Development – Increasing participation in global industry events and executing targeted brand-building initiatives 4. Technology Advancement – Systematically filing patents to protect core innovations and build intellectual property assets

Management believes these initiatives will drive sustained financial improvement. The Company will continue to monitor and report on their operational and financial progress.

NOTE 4 – DEFERRED SHARE ISSUANCE COST

On January 25, 2025, the Company entered into an Equity Purchase Agreement with Williamsburg Venture Holdings, LLC, a Nevada limited liability company, pursuant to which the Investor agreed to invest up to $5,000,000 over a 24-month period. During the term, the Company shall be entitled to put to Williamsburg, and Williamsburg shall be obligated to purchase, such number of shares of the Company’s common stock and at such price as are determined in accordance with the Equity Purchase Agreement. The per share purchase price for the Williamsburg Put Shares will be equal to 90% the lowest traded price of the Common Stock on the principal market during the five (5) consecutive trading days immediately preceding the date which Williamsburg received the Williamsburg Put Shares as DWAC Shares in its brokerage account (as reported by Bloomberg Finance L.P., or other reputable source).

On March 6, 2025, the Company amended the Equity Purchase Agreement with Williamsburg Venture Holdings, LLC to increase the maximum commitment amount from $5 million to $10 million. The Company shall issue up to 270,000 commitment shares to Williamsburg. These shares will be earned and issued in tranches according to the following milestones:

	·	50% of the commitment shares (135,000 shares) issued on the execution date

	·	50% of the commitment shares (135,000 shares) will be issued once the investor reaches 50% of the maximum commitment amount.

11During ~~Table~~the nine months ended September 30, 2025, upon the execution of ~~Contents~~the Equity Purchase Agreement, the Company issued 135,000 shares of common stock valued at $249,750 as commitment shares to the investor. During the nine months ended September 30, 2025, the Company also made a $5,000 payment to the investor as documentation fee for the reparation of the Equity Purchase Agreement and Registration Rights Agreement.

~~During~~As ~~the~~of ~~six~~September ~~months ended June~~ 30, 2025, ~~upon~~ the ~~execution~~deferred ofshare ~~the~~issuance ~~Equity~~cost ~~Purchase~~aggregated ~~Agreement,~~to ~~the Company issued 135,000 shares of common stock valued at~~ $~~249~~254,750 ~~as commitment shares to the investor~~. ~~During~~These ~~the~~costs ~~six~~are ~~months~~deferred ~~ended~~and ~~June~~will ~~30,~~be ~~2025,~~deducted from the ~~Company~~proceeds ~~also~~from ~~made~~future ~~$5,000~~stock issuance to the investor asunder ~~documentation fee for~~ the ~~reparation of the~~ Equity Purchase Agreement ~~and Registration Rights Agreement~~.

As10 Table of June 30, 2025, the deferred share issuance cost aggregated to $254,750. These costs are deferred and will be deducted from the proceeds from future stock issuance to the investor under the Equity Purchase Agreement.Contents

NOTE 5 – LOAN PAYABLE

On September 15, 2024, the Company entered into a loan agreement with a non-affiliate party at $128,401 to support operating expense of the Company. The loan has a maturity date of September 15, 2026 and interest rate at 8% per annum. During the nine months ended September 30, 2025, repayment of $25,000 was made. As of September 30, 2025 and December 31, 2024, the loan payable was $103,401 and $128,401, respectively.

On November 25, 2024, Goldfinch Group Holdings Ltd. entered into a loan agreement with a non-affiliate party at $20,041 (CNY145,172) to support legal set-up cost of the Company. The loan has a maturity date of November 25, 2026 and interest rate at 10% per annum.

On March 31, 2025, the Company entered into a loan agreement with a non-affiliate party at $41,820 to support operating expense of the Company. The loan has a maturity date of March 31, 2027 and interest rate at 8% per annum.

On June 30, 2025, the Company entered into a loan agreement with the same non-affiliate party at $6,800 to support operating expense of the Company. The loan has a maturity date of June 30, 2027 and interest rate at 8% per annum. ~~As of June 30, 2025, the loan payable to the non-affiliate was $48,620.~~

OnAs ~~March~~of 31September 30, 2025, the ~~Company entered into a~~ loan ~~agreement~~payable ~~with~~to athe non-affiliate ~~party~~was at $548,~~000 to support operating expense of the Company~~620. ~~The loan has a maturity date of March 31, 2027 and interest rate at 8% per annum.~~

~~During~~On March 31, 2025, the ~~six~~Company ~~months~~entered ~~ending~~into ~~June~~a ~~30,~~loan ~~2025~~agreement ~~and~~with ~~2024~~a non-affiliate party at $5,000 ~~interest~~to support operating expense ~~was~~of $7the Company. The loan has a maturity date of March 31,~~119~~ 2027 and $3interest rate at 8% per annum. During the nine months ended September 30,~~987~~ 2025, ~~respectively~~repayment of $5,000 was made. As of ~~June~~September 30, 2025 and December 31, 2024, the ~~accrued~~loan ~~interest~~ payable was $~~10,373~~0 and $35,~~253~~000, respectively.

During the nine months ending September 30, 2025 and 2024, interest expense was $11,224 and $3,987, respectively. As of ~~June~~September 30, 2025 and December 31, 2024, the ~~loan~~accrued interest payable was $~~202~~14,~~062~~477 and $~~148~~3,~~442~~253, respectively.

As of September 30, 2025 and December 31, 2024, the loan payable was $172,062 and $148,442, respectively.

NOTE 6 – CONVERTIBLE NOTE PAYABLE

On November 8, 2023, the Company issued a convertible promissory note to a non-affiliate at $153,520. The convertible note is non-interest bearing, has a maturity date of November 8, 2024 and is convertible at $0.03 per share of the Company’s common stock. On August 21, 2024, the non-affiliate transferred and assigned the convertible note to another non-affiliate.

On March 06, 2025, the convertible note was fully converted into 5,117,333 shares of common stock.

As of ~~June~~September 30, 2025 and December 31, 2024, convertible note payable was $0 and $153,520, respectively.

Table of Contents

NOTE 7 – RELATED PARTY TRANSACTIONS AND BALANCES

Loan payable – related parties

Effective June 15, 2018, the Company entered a loan agreement with its former CEO. The lender agreed to lend a total of $50,000 payable in applicable instalments over the Term of the loan. The CEO agreed to an interest rate of 0% and a term of 5 years. Effective October 6, 2022, the CEO agreed to increase maximum amount of the loan to $100,000 and extend the term to 7 years or until June 15, 2025. During the three months ended March 31, 2024, the former director for the Company who resigned on August 28, 2024 upon change of control, made payments to vendors on behalf of the Company of $27,491. During the ~~three~~six months ended ~~March~~June 3130, 2024, imputed interest of $13,~~329~~321 was incurred and recorded to additional paid-in capital. Upon his resignation on August 28, 2024, the loan to the former director of $104,696 was forgiven and recorded to additional paid in capital. The amount due under to loan was $0 as of ~~June~~September 30, 2025 and December 31, 2024, respectively.

During the ~~six~~nine months ending ~~June~~September 30, 2025 and 2024, the current director of the Company, who was appointed on October 28, 2024, made payment to vendors of $23,~~016~~045 and $0 on behalf of the Company, respectively. During the nine months ended September 30, 2025, she was repaid at $24,000. As of ~~June~~September 30, 2025 and December 31, 2024, the amount due to the director of the Company was $251,~~170~~199 and $2,154, respectively.

12During ~~Table~~the nine months ended September 30, 2025, the director of ~~Contents~~Goldfinch Group Holdings Ltd. made payment on incorporation and registration cost on behalf of its wholly subsidiary Crestar Holding Ltd. of $2,013. As of September 30, 2025, the amount due to the director of the Goldfinich was $2,013

~~Due~~As ~~from~~of September 30, 2025 and December 31, 2024, the amount due to the related ~~party~~parties was $13,212 and $2,154, respectively.

As of June 30, 2025 and December 31, 2024, the amount due from the related party was $15,000 from a related company which holds 30% interest in Goldfinch Group Holdings Ltd.

NOTE 8 - EQUITY

The Company has 75,000,000, $0.001 par value shares of common stock authorized.

During the ~~three~~nine months ended ~~March~~September 3130, 2025, the Company issued an aggregate of ~~221~~15,570,000 shares of common stock to consultants for service rendered valued at $~~408~~27,~~850~~888,890.

During the ~~three~~nine months ended ~~March~~September 3130, 2025, upon the execution of the Equity Purchase Agreement with Williamburg Venture Holding, LLC, the Company issued an aggregate of 135,000 shares of common stock valued at $249,750 as commitment shares.

OnDuring ~~March~~the 06nine months ended September 30, 2025, a convertible note of $153,250 was fully converted to 5,117,333 shares of common stock.

~~During~~On ~~the~~August ~~three months ended June 30~~20, 2025, the Company issued ~~an aggregate of~~ 3,~~395~~000,000 shares of common stock toat ~~consultants~~$2.00 ~~for~~per ~~service~~share ~~rendered~~with ~~valued~~a atfair value of $6,~~651~~000,~~250~~000 to acquire the remaining 30% equity interest in Goldfinch Group Holdings Ltd.

AsOn ofAugust ~~June 30~~25, 2025 ~~and December 31~~, ~~2024,~~ the Company issued ~~and~~10,000,000 ~~outstanding~~shares of common stock ~~was~~at $1.25 per share with a fair value of $12,~~915~~500,~~093~~000 ~~and~~as ~~4,046,760~~initial ~~shares,~~consideration ~~respectively~~for the acquisition of 51% equity interest in SolanAI Global Ltd.

~~NOTE~~On 9September –30, ~~SEGMENT~~2025, ~~REPORTING~~the Company issued 10,000,000 restricted shares of common stock at $0.17 per share with a fair value of $1,700,000 as initial consideration for the acquisition of 100% equity interest in Xirangsheng (Shenzhen) Health Technology Co., Ltd. On September 30, 2025, the Company completed the acquisition of 100% of XRS

As of September 30, 2025 and December 31, 2024, the issued and outstanding common stock was 47,869,093 and 4,046,760 shares, respectively.

Stock Payable

On August 12, 2025, the Company accrued stock payable of $50,000 for 25,000 restricted common stock payable upon 6 months from effective date February 12, 2025 per consulting agreement. (Note 10)

Table of Contents

NOTE 9 – ACQUISITION

Xirangsheng (Shenzhen) Health Technology Co., Ltd.

The acquisition was closed on September 30, 2025. XRS has been included in our consolidated balance sheets since the acquisition date.

The following table summarizes the preliminary identifiable assets acquired and liabilities assumed upon acquisition of XRS and the calculation of contingent liability:

Total purchase price	$	1,700,000

Bank		1,458
Prepaid Expense		6,644
Other Receivable		2,743
Intangible Assets		24,577,000
Total identifiable assets		24,587,845

Other Payable		(12,564	)
Total identifiable liabilities		(12,564	)

Net assets		24,575,281

Contingent Liability	$	(22,875,281	)

The Company, on consolidation of the acquired entity, has included the value of $24,575,281 and a contingent liability of $22,875,281. The contingent liability valuation is pending the independent valuation report of the acquired entity and the possibility for additional share based payments to be made within 60 days of receipt and the results of the report.

SolanAI Global Ltd.

On August 25, 2025, the Company entered into a share exchange agreement with Crestar Holdings Ltd., wholly owned subsidiary of Goldfinch Group Holdings Ltd., and Hailiang Li for the acquisition of 51% equity interest in SolanAI Global Ltd. through the issuance of 10,000,000 restricted common shares as initial consideration. The Company may issue up to 5,000,000 additional shares based on independent SolanAI’s valuation completed within 120 days, subject to Board approval and additional SEC disclosure. On August 25, 2025, the Company issued 10,000,000 restricted shares of common stock at $1.25 with a fair value of $12,500,000 as initial consideration for the acquisition.

The acquisition was closed on August 25, 2025. SolanAI has been included in our consolidated balance sheets since the acquisition date.

The following table summarizes the preliminary liabilities assumed upon acquisition of SolanAI and the calculation of goodwill:

Total purchase price	$	12,500,000

Total identifiable assets		-

Other Payable		(2,252	)
Total identifiable liabilities		(2,252	)

Net assets (liabilities)		(2,252	)

Non-controlling interest		1,103
Total net assets (liabilities)		(1,149	)

Goodwill	$	12,501,149

NOTE 10 – SEGMENT REPORTING

Operating segments comprised of the components of an entity in which separate information is available for evaluation by the Company’s chief operating decision maker, or group of decision makers, in determining how to allocate resources in evaluating performance. The Company consists of a single reporting segment: AI technology services. This segment is comprised of the Company's efforts to provide advanced AI solutions and related strategic consulting services. The Company’s chief operating decision maker (“CODM”) is its Chief Executive Officer.

Since September 2024, the Company has focused on comprehensive strategic transformation and business restructuring efforts. This included establishing a new management team, defining a new AI-centric business direction, and developing innovative AI-driven products and service portfolios. The Company is actively building a comprehensive AI ecosystem that integrates advanced AI Social Agent technology, multimodal intelligent interaction systems, and intelligent business process automation solutions.

As of ~~June~~September 30, 2025, the company reported revenue of $50100,000, primarily from strategic consulting services to provide AI-Driven Ecosystem Product to client. During this period, we focused on strategic transformation and comprehensive business restructuring: Our newly formed core management team established a development strategy centered around AI Social Agent technology, developing a series of innovative products and services around this focus.

With the full launch of our next-generation AI Social Agent products, we anticipate driving sustained revenue growth from AI technology services.

Table of Contents

The accounting policies of the translation service segment are as described in the summary of significant accounting policies. The CODM will evaluate the performance of the translation service segment based on the Company’s net income (loss) as reported in the Statements of Operations upon resumption of the translation services. The Company’s segment assets are reported on the Balance Sheets.

The Company currently focuses on the cost control and debt and equity financing to achieve its reorganization objective. Upon the resumption of translation service, the CODM will review performance based on gross profit, operating profit, net earnings and net earnings excluding the impact of the fair value adjustment, a non-GAAP financial measure. Operating profit will be reviewed to monitor the operating and administrative expenses of the Company.

13NOTE ~~Table~~11 of– ~~Contents~~COMMITMENT AND CONTINGENCIES

NOTE 10 – COMMITMENT AND CONTINGENCIES

On February 12, 2025, the Company entered into an agreement with 5D Partners LLC, a non-affiliate investment banker and financial advisor for fundraising, private placements, mergers and acquisitions and related services. The agreement commences on February 12, 2025, the effective date, and continues for a period of 12 months.

The Company will issue common stock as follows:

	·	25,000 restricted common stock upon 6 months of the effective date (stock payable as of September 30, 2025); and
	·	25,000 restricted common stock upon 12 months of the effective date.

~~NOTE~~On 11September –30, ~~SUBSEQUENT~~2025, ~~EVENTS~~the Company entered into a share exchange agreement with Crestar Holdings Ltd. (Note 10) for the acquisition of XRS. The Company made an initial share payment valued at $1,700,000 and may issue additional shares subject to an independent valuation report. The contingent liability was calculated based on the net value of the XRS entity less the initial share payment. The Company has included a contingent liability of $22,875,281 pending the results of the report.

InNOTE ~~accordance~~12 ~~with~~– ~~ASC~~SUBSEQUENT 855, “Subsequent Events,” the Company has analyzed its operations subsequent to June 30, 2025 to the date these financial statements were issued and has determined that it has the below material subsequent event to disclose in these financial statements.EVENTS

OnIn ~~July~~accordance ~~8, 2025, the Company executed a Letter of Intent ("LOI")~~ with ~~SolanAI~~ASC ~~Global~~855, ~~Limited~~“Subsequent ~~(a Hong Kong-registered company)~~Events,” ~~outlining a proposed transaction whereby TRSO would acquire 51% of SolanAI's issued and outstanding shares through~~ the ~~issuance~~Company ofhas ~~TRSO~~analyzed ~~common~~its ~~stock~~operations ~~(the~~subsequent ~~"Transaction"). The LOI specifies that the Transaction will be executed based on a mutually agreed valuation of SolanAI~~ to beSeptember ~~determined following completion of due diligence. The agreement is contingent upon several conditions~~30, ~~including~~2025 ~~satisfactory~~to ~~due diligence results, approval by both companies' boards of directors,~~ the ~~absence~~date ofthese ~~any~~financial ~~material~~statements ~~adverse~~were ~~changes,~~issued and ~~receipt~~has ofdetermined all required third-party consents. The LOI incorporates mutual confidentiality provisions and grants either party the right to terminate the agreement in writing should due diligence findings prove unsatisfactory. It should be noted that ~~this~~it ~~LOI~~has ~~does not establish a binding commitment to consummate~~ the ~~Transaction,~~below material assubsequent ~~final~~event ~~execution remains subject~~ to ~~the~~disclose ~~negotiation~~in ~~and~~these ~~execution~~financial ~~of definitive agreements~~statements.

In ~~July~~October 2025, the Company issued an aggregate of 112,~~500~~190,000 shares of common stock to consultants for service rendered valued at $54,~~875~~618,~~000~~045.

On October 14, 2025, the Company obtained written consent by the holders of the majority of the voting power of the Company's capital stock approving the adoption of the Company’s 2025 Stock Incentive Plan (the “Plan”). The Plan allows the Board of Directors of the Company to grant incentive stock options, nonqualified stock options and restricted stock awards to officers, directors, employees and consultants of the Company. At the time of consent, there were 7,000,000 shares of common stock of the Company reserved for issuance under the Plan.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

~~FORWARD-LOOKING STATEMENTS~~Overview

~~This annual report contains forward-looking statements~~Transuite.Org ~~These statements relate to future events or our future financial performance~~Inc. ~~These statements often can be identified by~~ (the ~~use of terms such as~~ “~~may~~Company,” “~~will~~we,” “~~expect~~us,” ~~“believe,”~~or “~~anticipate,~~our” ~~“estimate~~,” ~~“approximate”~~Ticker: orTRSO ~~“continue,”~~) oris ~~the~~a ~~negative~~technology ~~thereof.~~company Wefocused ~~intend~~on ~~that~~innovation ~~such~~in ~~forward-looking statements be subject to~~ the ~~safe~~artificial ~~harbors~~intelligence ~~for~~(AI) ~~such~~sector, ~~statements.~~having Wesuccessfully ~~wish~~completed toa ~~caution~~strategic ~~readers~~transformation ~~not~~from toa ~~place~~provider ~~undue~~of ~~reliance~~traditional onlanguage ~~any~~services ~~such~~to ~~forward-looking~~a ~~statements,~~provider ~~which speak only as~~ of ~~the~~AI-driven ~~date made~~solutions. ~~Any~~The ~~forward-looking statements represent management~~Company’s ~~best~~mission ~~judgment~~is as to ~~what~~develop ~~may occur in the future. However, forward-looking statements are subject to risks, uncertainties~~ and ~~important~~deploy ~~factors~~advanced ~~beyond~~AI ~~our~~technologies ~~control~~ that ~~could~~empower ~~cause~~clients ~~actual~~across ~~results~~various ~~and~~industries ~~events~~ to ~~differ~~enhance ~~materially~~operational ~~from~~efficiency, ~~historical~~strengthen ~~results~~customer ofengagement, ~~operations~~ and ~~events~~expand ~~and~~their ~~those~~global ~~presently~~market ~~anticipated or projected~~reach. WeThe ~~disclaim~~Company ~~any~~is ~~obligation~~led ~~subsequently~~by toa ~~revise~~diverse ~~any~~team ~~forward-looking~~of ~~statements~~international totalent ~~reflect~~with ~~events~~deep orprofessional ~~circumstances~~expertise ~~after~~and ~~the~~international ~~date~~experience ofin ~~such~~AI, ~~statement~~Web3.0, ~~or to reflect~~ the ~~occurrence~~Internet of ~~anticipated~~Things or(IoT), ~~unanticipated~~and ~~events~~financial technology.

~~GENERAL~~The Company executes its AI development strategy through its wholly-owned subsidiary, Goldfinch Group Holdings Ltd., and its underlying holding structure, which provides a solid organizational framework for our technological integration and global business expansion.

~~Transuite.Org~~Business ~~Inc.(“TRSO”)~~and has successfully completed a transformative evolution from a traditional translation service provider to a cutting-edge artificial intelligence solutions company, positioning itself at the forefront of the rapidly expanding AI market. Strategy

~~Led~~For bythe anthird ~~internationally~~quarter ~~recognized~~ended ~~team~~September ~~with~~30, ~~deep~~2025, ~~expertise~~the Company got revenue from ~~prestigious~~providing ~~institutions~~AI ~~including~~ecosystem-related ~~Tsinghua~~products ~~University,~~and consulting services. We believe this result provides an initial validation of the ~~Company~~viability ~~has~~of ~~developed~~our business model and the ~~revolutionary~~market demand for our solutions. The Company leverages its proprietary technology stack, including advanced AI ~~Social~~models, ~~Agent~~big ~~platform~~data analytics capabilities, ~~establishing~~and ~~TRSO~~Web3/blockchain asinfrastructure, to establish a differentiated competitive advantage in the global ~~pioneer~~market infor ~~"AI~~intelligent ~~Workforce~~customer assupport aand ~~Service"~~cross-lingual ~~(AWaaS).~~automation services.

~~This~~Recent ~~strategic~~Developments ~~transformation, combined with the formation of Goldfinch Group Holdings Ltd. where TRSO holds a commanding 70% controlling interest, has created a robust foundation for sustainable growth~~ and ~~market~~Strategic ~~leadership in the AI sector.~~Transactions

During the third quarter of 2025, the Company pursued a series of strategic transactions to accelerate business growth and solidify its market position. These initiatives are designed to enhance our technological capabilities, broaden our product portfolio, and ultimately increase shareholder value.

Proposed Material Acquisitions

	·	Proposed Transaction with Fujian Wochong Intelligent Technology Co., Ltd.: On September 15, 2025, the Company entered into an LOI to acquire a 51% equity interest in Fujian Wochong Intelligent Technology Co., Ltd. (“Wochong”), a National High-Tech Enterprise in China. Wochong specializes in intelligent electric vehicle (EV) charging solutions and possesses a comprehensive product portfolio, including high-end intelligent charging piles, charging security management systems, and an IoT and AI cloud platform. This proposed acquisition is intended to enable the Company to enter the rapidly growing EV charging market and to explore synergies between AI technology and IoT infrastructure, including the joint development of applications for the tokenization of charging assets as Real World Assets (RWAs). The consummation of this transaction is contingent upon the results of due diligence and execution of a definitive agreement

	·	Proposed Transaction with SYD GOLDX PTY LTD: On September 26, 2025, the Company entered into an LOI to acquire a 51% equity interest in SYD GOLDX PTY LTD (“SGX”), a licensed digital currency exchange in Australia. This proposed transaction is intended to integrate digital currency exchange functionalities into the Company’s existing technology ecosystem, with the goal of further strengthening our Web3 and fintech service capabilities. The consummation of this transaction is also contingent upon the results of due diligence and execution of a definitive agreement

Completed Material Acquisition

	·	Completion of the Acquisition of SolanAI Global Limited: On July 8, 2025, the Company entered into a Letter of Intent (LOI) to acquire a 51% equity interest in SolanAI Global Limited, a Hong Kong-based AI technology company(“SolanAI”). Subsequently, on August 25, 2025, the parties entered into a definitive Share Exchange Agreement. Pursuant to the agreement, the Company has issued restricted shares of its common stock as initial consideration and may issue up to an additional shares based on a future independent valuation of SolanAI. This transaction, which is subject to the satisfaction of closing conditions, is expected to strengthen the Company’s AI research and development capabilities and expand its presence in the Asian market upon completion

	·	Completion of the Acquisition of Xirangsheng (Shenzhen) Health Technology Co., Ltd.: On September 30, 2025, the Company completed the acquisition of 100% of the equity of Xirangsheng (Shenzhen) Health Technology Co., Ltd. (“XRS”). XRS is an innovative enterprise that combines AI technology with Traditional Chinese Medicine (TCM) principles. Its core assets include an AI social agent based on a massive TCM knowledge base, a 21-day health supervision system, and a series of over 300 proprietary e-books on TCM health. This acquisition marks the Company’s official entry into the AI-driven wellness technology sector. The transaction was structured as a share exchange, with issued restricted shares of its common stock as initial consideration and includes an earn-out provision based on the future valuation of XRS

The strategic initiatives described above reflect the Company’s commitment to building a diversified and vertically integrated AI-centric business ecosystem. We are actively pursuing both horizontal and vertical industry integration with the aim of strengthening our technological barriers to entry, expanding our market penetration, and leveraging our corporate structure to effectively integrate global resources and grow our international footprint. The proposed transactions are expected to complete due diligence and proceed to the definitive agreement stage by Dec 31, 2025. Our goal is to increase value to meet the requirements to uplist to Nasdaq or NYSE and bring more benefits to our shareholders and contribute the society as well.

Forward-Looking Statements

This Business section contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These statements are based on our current expectations, assumptions, estimates, and projections and involve known and unknown risks and uncertainties. Although we believe that the expectations reflected in these forward-looking statements are reasonable, actual results may differ materially from the results predicted in the forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements.

Outlook

We believe that the Company’s strategic transformation and recent strategic initiatives have established a foundation for our future growth and have positioned us favorably in the rapidly expanding AI market. In the future, we will focus on the successful integration of our acquired businesses, the continued development of innovative AI solutions, and the expansion of our global customer base. We believe that through our relentless pursuit of innovation, the leadership of our distinguished management team, and disciplined strategic execution, we are committed to creating long-term value for our shareholders.

Table of Contents

~~OUR~~Results ~~CURENT~~of ~~BUSINESS~~Operations for the three months ended September 30, 2025 and September 30, 2024

~~TRSO~~The ~~has~~following ~~successfully~~summary ~~launched~~of ~~its~~our ~~flagship~~operations AIshould ~~Social~~be ~~Agent~~read ~~platform,~~in ~~delivering~~conjunction ~~breakthrough~~with AIour ~~workforce~~audited ~~solutions~~financial ~~that~~statements ~~seamlessly~~for ~~integrate~~the ~~with~~three ~~major~~months ~~global~~ended ~~platforms~~September ~~including WhatsApp~~30, ~~Telegram,~~2025 and ~~WeChat.~~2024, ~~The~~which ~~Company's~~are ~~innovative~~included ~~AWaaS model enables enterprises to deploy sophisticated AI employees that provide 24/7 customer engagement while dramatically improving operational efficiency~~herein.

With the achievement of $50,000 in revenue during the first half of 2025 from AI-Driven Ecosystem Product Planning consulting services, TRSO has demonstrated strong commercial viability and market demand for its solutions.

	Three Months Ended
	September 30,
	2025		2024		Changes		%

Revenue	$	65,000	$	-	$	65,000		100	%
Operating Expenses		20,939,131		190,183		20,748,948		10,910	%
Other expenses		4,105		-		4,105		100	%
Net Loss	$	20,878,236	$	190,183	$	20,688,053		10,878	%

~~The~~During ~~Company's~~the ~~comprehensive~~three AImonths ~~ecosystem~~ended ~~addresses~~September ~~critical~~30, ~~needs~~2025 ~~across~~and ~~healthcare~~2024, ~~e-commerce~~the Company generated revenue of $65,000 and ~~education sectors~~$0, ~~positioning~~respectively. ~~TRSO~~During tothe ~~capture~~three ~~significant~~months ~~market~~ended ~~share~~September in30, 2025, the ~~multi-billion~~Company ~~dollar~~generated revenue from its AI-Driven ~~services~~Ecosystem ~~market~~Product Planning consulting service.

~~RECENT~~Net ~~BUSINESS~~loss ~~DEVELOPMENT~~increased to $20,878,236 for the three months ended September 30, 2025 from $190,183 for the three months ended September 30, 2024 mainly due to the increase in operating expenses.

~~TRSO~~Operating ~~has~~expenses ~~achieved~~for ~~remarkable~~three ~~progress~~months ~~through~~ended ~~strategic~~September ~~initiatives~~30, ~~that~~2025 ~~have~~increased ~~strengthened~~to ~~its~~$20,939,131 ~~market~~from ~~position~~$190,183 for the three months ended September 30, 2024 mainly due to the increase in stock-based compensation, audit fees, accounting fees and ~~growth~~legal ~~prospects~~fees. During the three months ended September 30, 2025, the Company incurred stock-based compensation of $20,828,790 from the issuance of 11954,000 shares of common stock to consultants for service rendered.

~~The~~Results ~~Company~~of ~~secured~~Operations upfor tothe ~~$10~~nine ~~million~~months inended ~~committed~~September ~~funding~~30, ~~through~~2025 ~~its~~and ~~amended~~September ~~equity purchase agreement with Williamsburg Venture Holdings~~30, ~~LLC, providing substantial financial resources for expansion.~~ 2024

The ~~execution~~following summary of aour ~~Letter~~operations ofshould ~~Intent~~be toread ~~acquire~~in ~~51%~~conjunction ofwith ~~SolanAI~~our ~~Global~~audited ~~Limited~~financial ~~represents~~statements afor ~~transformative~~the ~~opportunity~~six tomonths ~~significantly~~ended ~~enhance~~September ~~technological~~30, ~~capabilities~~2025 and ~~accelerate~~2024, ~~market~~which ~~penetration.~~are included herein.

Additionally, the strategic partnership with 5D Partners LLC for investment banking and M&A advisory services positions TRSO to pursue additional growth opportunities and optimize capital structure.

	Nine Months Ended
	September 30,
	2025		2024		Changes		%

Revenue	$	115,000	$	-		115,000		100	%
Operating expenses		28,069,179		281,685		27,787,494		9,865	%
Other expenses		11,224		3,987		7,237		182	%
Net Loss	$	27,965,403	$	285,672	$	27,794,731		9,730	%

~~These~~During ~~developments~~the nine months ended September 30,~~combined~~ ~~with~~2025 ~~systematic~~and ~~patent~~2024, ~~filing~~the ~~initiatives~~Company togenerated ~~protect~~revenue ~~core~~of ~~innovations~~$115,000 ~~demonstrate~~and ~~management's~~$0, ~~commitment~~respectively. toDuring ~~building~~the ~~sustainable~~nine ~~competitive~~months ~~advantages~~ended ~~and~~September ~~long~~30, 2025, the Company generated revenue from its AI-~~term~~Driven ~~shareholder~~Ecosystem ~~value~~Product Planning consulting service.

~~Results~~Net ofloss ~~Operations~~increased to $27,965,403 for the ~~three~~nine months ended ~~June~~September 30, 2025 ~~and~~from ~~June~~$285,672 for the nine months ended September 30, 2024 mainly due to the increase in operating expense.

~~The~~Operating ~~following~~expenses ~~summary~~for ofnine ~~our~~months ~~operations~~ended ~~should~~September be30, ~~read~~2025 increased to $28,069,179 from $281,685 for the nine months ended September 30, 2024 mainly due to the increase in ~~conjunction~~stock-based ~~with~~compensation, ~~our~~audit ~~audited~~fees, ~~financial~~accounting ~~statements~~fees ~~for~~and legal fees. During the ~~three~~nine months ended ~~June~~September 30, 2025, ~~and~~the ~~2024~~Company incurred stock-based compensation of $27,938,890 ~~which~~from ~~are~~the ~~included~~issuance ~~herein~~of 15,570,000 shares of common stock to consultants for service rendered.

	Three Months Ended
	June 30,
	2025		2024		Changes		%
Revenue	$	50,000	$	-	$	50,000		100	%
Operating Expenses		6,645,444		42,614		6,602,830		15,495	%
Other expenses		5,326		2,658		2,668		100	%
Net Loss	$	6,600,770	$	45,272	$	6,555,498		14,480	%

During the three months ended June 30, 2025 and 2024, the Company generated revenue of $50,000 and $0, respectively. During the three months ended June 30, 2025, the Company generated revenue from its AI-Driven Ecosystem Product Planning consulting service.

Net loss increased to $6,600,770 for the three months ended June 30, 2025 from $45,272 for the three months ended June 30, 2024 mainly due to the increase in operating expense.

Operating expenses for three months ended June 30, 2025 increased to $6,645,444 from $42,614 for the three months ended June 30, 2024 mainly due to the increase in stock-based compensation, audit fees, accounting fees and legal fees. During the three months ended June 30, 2025, the Company incurred stock-based compensation of $6,651,250 from the issuance of 3,395,000 shares of common stock to consultants for service rendered.

Table of Contents

Results of Operations for the six months ended June 30, 2025 and June 30, 2024

The following summary of our operations should be read in conjunction with our audited financial statements for the six months ended June 30, 2025 and 2024, which are included herein.

	Six Months Ended
	June 30,
	2025		2024		Changes		%
Revenue	$	50,000	$	-		50,000		100	%
Operating expenses		7,128,772		91,502		7,037,270		7,691	%
Other expenses		8,395		3,987		4,408		111	%
Net Loss	$	7,087,167	$	95,489	$	7,041,678		7,374	%

During the six months ended June 30, 2025 and 2024, the Company generated revenue of $50,000 and $0, respectively. During the six months ended June 30, 2025, the Company generated revenue from its AI-Driven Ecosystem Product Planning consulting service.

Net loss increased to $7,087,167 for the six months ended June 30, 2025 from $95,489 for the six months ended June 30, 2024 mainly due to the increase in operating expense.

Operating expenses for six months ended June 30, 2025 increased to $7,128,772 from $91,502 for the six months ended June 30, 2024 mainly due to the increase in stock-based compensation, audit fees, accounting fees and legal fees. During the six months ended June 30, 2025, the Company incurred stock-based compensation of $7,060,100 from the issuance of 3,616,000 shares of common stock to consultants for service rendered.

Liquidity and Capital Resources

The following table provides selected financial data about the Company as of ~~June~~September 30, 2025 and December 31, 2024

Working Capital

	As of		As of
	June 30,		December 31,
	September 30,		December 31,
	2025		2024			Changes			%
Current Assets	$	~~330~~299,~~530~~842	$	31,103		$	~~299~~268,~~427~~739			~~963~~864	%
Current Liabilities	$	88153,~~442~~042	$	225,294		$	(~~136~~72,~~852~~252	)	(~~61%)~~32		%)
Working Capital Deficiency	$	242,088	$	(194,191	)	$	162,575		(84%)
Working Capital (Deficiency)	$	146,800	$	(194,191	)	$	196,487		(101		%)

As at ~~June~~September 30, 2025, our Company had a working capital of $~~242~~146,~~088~~800 compared with a working capital deficiency of $194,191 as at December 31, 2024. The increase in working capital was primarily due to the increase in deferred share issuance cost of $254,750, accounts receivable of $5015,000 and ~~prepaid~~other ~~expense~~receivable and prepayment of $1016,~~680~~062 and the decrease in convertible note of $153,250.

17 Table of Contents

Cash Flows

~~Six~~Nine months ended ~~June~~September 30, 2025, compared to the ~~six~~nine months ended ~~June~~September 30, 2024:

	Six Months Ended
	Nine Months Ended
	June 30,
	September 30,
	2025			2024			Changes			%
Cash flows used in operating activities	$	(9228,~~639~~209	)	$	(35123,~~026~~877	)	$	~~(57~~95,~~613~~668	)	(77	~~165~~	%)
Cash flows used in investing activities		-			-			-			-
Cash flows provided by investing activities		1,458			-			1,458			100	%
Cash flows provided by financing activities		7624,~~636~~678			35163,~~026~~625			41(138,~~610~~947	)	(85	~~119~~	%)
Net changes in cash	$	(162,~~003~~073	)	$	-39,748		$	(1641,~~003~~821	)	(100%)		%)

Cash Flow from Operating Activities

We have not generated positive cash flow from operating activities. During the ~~six~~nine months ended ~~June~~September 30, 2025, net cash used in operating activities was $9228,~~639~~209 compared to $35123,~~026~~877 used during the ~~six~~nine months ended ~~June~~September 30, 2024.

Cash flows used in operating activities during the ~~six~~nine months ended ~~June~~September 30, 2025, comprised of a net loss of $727,~~087~~965,~~167~~403, which was reduced by amortization of $69,~~456~~684, stock-based compensation of $727,~~060~~938,~~100~~890 and was increased by net changes in operating assets and liabilities of $7211,~~028~~380.

Cash flows used in operating activities during the ~~six~~nine months ended ~~June~~September 30, 2024, comprised of a net loss of $95285,~~489~~672, which was reduced by amortization of $69,~~456~~842, imputed interest of $3,321 and net changes in operating assets and liabilities of $50148,~~686~~632.

Cash Flow from Investing Activities

During the ~~six~~nine months ended ~~June~~September 30, 2025, ~~and~~the ~~2024~~Company received $1,458 wefrom ~~did~~net ~~not~~funds ~~have~~from ~~any~~acquisition ~~investing~~of ~~activities~~Xirangsheng (Shenzhen) Health Technology Co., Ltd.

During the nine months ended September 30, 2024, we did not have any investing activities.

Table of Contents

Cash Flow from Financing Activities

During the ~~six~~nine months ended ~~June~~September 30, 2025 and 2024, we had net cash provided by financing activities of $7624,~~636~~678 and $35163,~~026~~625, respectively.

During the ~~six~~nine months ended ~~June~~September 30, 2025, we received advancement from non-affiliates of $53,620 offset by repayment to the non-affiliate of $30,000, and advancement from the ~~director~~directors of $2325,~~016~~058 for payment made to vendors on behalf of the Company offset by repayment to the director of $24,000.

During the ~~six~~nine months ended ~~June~~September 30, 2024, we received advancement from the former director of $35163,~~026~~625 for payment made to vendors on behalf of the Company.

Going Concern

As of the ~~six~~nine months ended ~~June~~September 30, 2025, we had an accumulated deficit of $728,~~545~~429,~~784~~710 and negative operating cash flow of $9228,~~639~~209 for ~~six~~nine months ended ~~June~~September 30, 2025.

While TRSO continues to invest heavily in its transformative growth strategy, the Company has demonstrated significant progress in strengthening its financial foundation and operational capabilities.

The improvement in working capital from a deficit of $194,191 to a positive $~~242~~146,~~088~~800 reflects effective financial management and successful execution of the business transformation. Management has implemented a comprehensive strategy focused on accelerating revenue growth through expanded client relationships, strategic acquisitions to enhance technology offerings, and systematic intellectual property development.

With committed funding of up to $10 million available through the Williamsburg agreement and strong early revenue generation demonstrating market validation, TRSO is well-positioned to achieve sustainable profitability and deliver exceptional returns to shareholders as the AI market continues its rapid expansion.

Off Balance Sheet Arrangements

We have no off-balance sheet arrangements including arrangements that would affect our liquidity, capital resources, market risk support and credit risk support or other benefits.

18 Table of Contents

Critical Accounting Policies

The preparation of financial statements in accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. A change in managements’ estimates or assumptions could have a material impact on our financial condition and results of operations during the period in which such changes occurred. Actual results could differ from those estimates. Our financial statements reflect all adjustments that management believes are necessary for the fair presentation of their financial condition and results of operations for the periods presented.

Fair Value of Financial Instruments

ASC 820 “Fair Value Measurements and Disclosures” establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.

These tiers include:

Level 1: defined as observable inputs such as quoted prices in active markets;

Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3: defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Table of Contents

The carrying value of cash, prepayments and the Company’s loan from shareholder approximates its fair value due to their short-term maturity.

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, “Revenue Recognition” following the five steps procedure:

Step 1: Identify the contract(s) with customers

Step 2: Identify the performance obligations in the contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price to performance obligations

Step 5: Recognize revenue when the entity satisfies a performance obligation

Recent Accounting Pronouncements

Management has considered all recent accounting pronouncements issued. Our Company’s management believes that these recent pronouncements will not have a material effect on our financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company”, we are not required to provide the information required by this Item.

19 Table of Contents

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by our company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management carried out an evaluation under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of ~~June~~September 30, 2025. Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures were not effective as of ~~June~~September 30, 2025.

Our disclosure controls and procedures reflect the company’s current stage of development and organizational structure. Currently, our Chief Executive Officer and Director assumes core responsibility for financial processes, including the identification, authorization, approval, accounting for, and disclosure of significant estimates, related-party transactions, and unusual transactions. We are evaluating and planning to implement additional control measures, including the introduction of independent review mechanisms, to further enhance the effectiveness and reliability of our internal controls.

Changes in Internal Control Over Financial Reporting

During the period covered by this report there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Internal Controls

Our management do not expect that our disclosure controls and procedures or our internal control over financial reporting are or will be capable of preventing or detecting all errors or all fraud. Any control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements, due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns may occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risk.

2019 Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

None

Item 1A. Risk Factors

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended ~~March~~September 3130, 2025, the Company issued an aggregate of ~~221~~11,954,000 shares of common stock to consultants for service rendered valued at $~~408~~20,~~850~~828,790.

~~During~~On ~~the~~August ~~three months ended March 31~~20, 2025, ~~upon~~ the ~~execution~~Company ofissued ~~the~~3,000,000 ~~Equity~~shares ~~Purchase~~of ~~Agreement~~common ~~with~~stock ~~Williamburg~~at ~~Venture~~$2.00 ~~Holding,~~per ~~LLC,~~share ~~the~~with ~~Company~~a ~~issued~~fair anvalue ~~aggregate~~ of ~~135~~$6,000,000 ~~shares~~to ofacquire ~~common~~the ~~stock~~remaining ~~valued~~30% atequity ~~$249,750~~interest asin ~~commitment~~Goldfinch ~~shares~~Group Holdings Ltd.

On ~~March~~August 0625, 2025, athe ~~convertible~~Company ~~note~~issued 10,000,000 shares of common stock at $~~153,250~~1.25 ~~was~~per ~~fully~~share ~~converted~~with toa 5fair value of $12,~~117~~500,~~333~~000 ~~shares~~as initial consideration for the acquisition of ~~common~~51% ~~stock~~equity interest in SolanAI Global Ltd.

~~During~~On ~~the~~September ~~three months ended June~~ 30, 2025, the Company issued ~~an aggregate of 3~~10,~~395~~000,000 restricted shares of common stock toat ~~consultants~~$0.17 ~~for~~per ~~service~~share ~~rendered~~with ~~valued~~a atfair value of $61,~~651~~700,~~250~~000 as initial consideration for the acquisition of 100% equity interest in Xirangsheng (Shenzhen) Health Technology Co., Ltd.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None

21 Table of Contents

Item 6. Exhibits

31.1		Certification of Chief Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act

32.1		Certification of Chief Executive Officer and Chief Financial Officer Under Section 1350 as Adopted Pursuant Section 906 of the Sarbanes-Oxley Act

2220 Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

Transuite.Org Inc.

Dated August 13, 2025	By:	/s/ Mengqing Fan
Dated November 18, 2025	By:	/s/ Mengqing Fan
		Mengqing Fan
		Title: CEO, Director

Dated August 13, 2025	By:	/s/ Wei Zhen
Dated November 18, 2025	By:	/s/ Wei Zhen
		Wei Zhen
		Title: CFO, Director

2321

Filing Compare · TRANSUITE.ORG INC.